Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Complications of t1 and t2 diabetes diagnosed in childhood; Gene therapy for sickle cell disease

Date Released: Jun 28 2017

Dr. Joseph Wolfsdorf discusses complications related to type 1 and type 2 diabetes in pediatric patients, and Dr. Michael DeBaun discusses a report of gene therapy for sickle cell disease. Dr. Nancy Sokol hosts.

Dr. WolfsdorfDr. Joseph Wolfsdorf is a Professor of Pediatrics at Harvard Medical School, and Director of the Diabetes Program at the Boston Children's Hospital.
Dr. DeBaunDr. Michael DeBaun is a Professor of Pediatrics and Medicine at Vanderbilt University and is Director of the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease.

Segment on diabetes in children (Dr. Wolfsdorf):

  1. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA 2017; 317:825.

Segment on gene therapy for sickle cell disease (Dr. DeBaun):

  1. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376:848.

Joseph I Wolfsdorf, MB, BCh Nothing to disclose

Michael R DeBaun, MD, MPH Nothing to disclose

Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

Date Released: Jun 14 2017

This episode features Dr. Richard Larson discussing the long-term outcomes of imatinib treatment for chronic myeloid leukemia, and Dr. Francisco Gonzalez-Scarano discussing the use of ocrelizumab for treatment of primary progressive multiple sclerosis. Dr. Jennifer Mitty hosts.

Dr. González-ScaranoDr. Francisco González-Scarano is Professor of Neurology and the John P. Howe Distinguished Chair in Health Policy at the University of Texas Health Science Center at San Antonio and Professor Emeritus of Neurology at the University of Pennsylvania.
Dr. LarsonDr. Richard Larson is Professor of Medicine and the Director of the Hematological Malignancies Clinical Research Program at the University of Chicago Pritzker School of Medicine.

Segment on Long-term follow-up of Imatinib in chronic myeloid leukemia (Dr. Richard Larson) :

  1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.

Segment on Ocrelizumab for primary progressive multiple sclerosis (Dr. Francisco González-Scarano):

  1. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376:209.

Francisco González-Scarano, MD Equity Ownership/Stock Options: Multiple, but traded by advisors without personal input [Pharmaceutical]. Other Financial Interests: NeuroLink [Venture Capital].

Richard A Larson, MD Grant/Research/Clinical Trial Support: Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Erytech [leukemia (eryaspase)]; Ariad [leukemia (ponatinib)]; Novartis [leukemia (nilotinib)]; Ambit Bioscience [leukemia (quizartinib)]; Daiichi Sankyo [leukemia (quizartinib)]; Celgene [leukemia (AG-221)]. Consultant/Advisory Boards: Novartis [leukemia (imatinib, nilotinib)]; Ariad Data Safety Monitoring Board [leukemia (ponatinib)]; CVS/Caremark [leukemia (drug prior authorization program)]; Pfizer [leukemia (gemtuzumab ozogamicin, inotuzumab)]; Celgene Data Safety Monitoring Board [leukemia (azacitidine, durvalumab)]; Bristol Meyers Squibb Data Safety Monitoring Board [leukemia (dasatinib)]; Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Jazz [leukemia (CPX-351)].

Transcatheter aortic valve implantation; Bariatric surgery for patients with diabetes mellitus

Date Released: May 31 2017

In this episode, Dr. Stephen Brecker discusses transcatheter aortic valve implantation for severe aortic stenosis in patients with intermediate surgical risk, and Dr. David McCulloch discusses outcomes of bariatric surgery for patients with diabetes mellitus.

Dr. BreckerDr. Stephen Brecker is Professor of Cardiology at St. George’s University of London, and Chief of Cardiology at St. George’s University Hospitals.
Dr. David McCullochDr. David McCulloch is Clinical Professor of Medicine at the University of Washington in Seattle.

Segment on transcatheter aortic valve implantation (Dr. Brecker):

  1. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376:1321.

Segment on bariatric surgery for patients with diabetes mellitus (Dr. McCulloch):

  1. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med 2017; 376:641.

Stephen JD Brecker, MD, FRCP, FESC, FACC Grant/Research/Clinical Trial Support: Medtronic [Transcatheter valves]. Speaker’s Bureau: Medtronic [Transcatheter valves]. Consultant/Advisory Boards: Medtronic; Boston Scientific [Transcatheter valves].

David K McCulloch, MD Nothing to disclose

Spirometry and asthma diagnosis; Baricitinib for the treatment of rheumatoid arthritis

Date Released: May 17 2017

This episode features Dr. Christopher Fanta, discussing the role of spirometry in the diagnosis of asthma; and Dr. James O’Dell, discussing baricitinib, a promising oral agent for the treatment of rheumatoid arthritis. Dr. Helen Hollingsworth hosts.

Dr. FantaDr. Christopher Fanta is Professor of Medicine at Harvard Medical School and Director of the Partner’s Asthma Center at Brigham and Women’s Hospital in Boston.
Dr. O'DellDr. James O'Dell is Professor of Internal Medicine, Chief of the Section of Rheumatology at the University of Nebraska Medical Center, and Director of the Rheumatoid Arthritis Investigative Network.

Segment on spirometry and asthma diagnosis (Dr. Fanta):

  1. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317:269.

Segment on baricitinib for the treatment of rheumatoid arthritis (Dr. O'Dell):

  1. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376:652.
  2. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior d5isease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017; 69:506.

Christopher H Fanta, MD Nothing to disclose

James R O'Dell, MD Consultant/Advisory Boards: Abbvie [Rheumatoid arthritis (TNF inhibitor)]; Lilly [Rheumatoid arthritis (JAK kinase inhibitor)]; BMS [Rheumatoid arthritis (abatacept)]; GlaxoSmithKline [Rheumatoid arthritis (anti-IL-6)]; Medac [Rheumatoid arthritis (methotrexate)].